## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application:

A. Mangel et al.,

Serial No.:

09/529050

Examiner:

P. Spivack

Filing Date:

5 April 2000

Art Unit:

1614

For:

**MEDICAMENTS** 

RECEIVED

NOV 02 2000

TECH CENTIER 1600/2900

Commissioner for Patents and Trademarks Washington D.C. 20231

## **RESPONSE**

Sir:

Responsive to the first Office Action mailed 29 August 2000, please amend and reconsider the instant application in view of the following amendments and remarks 0.00 to 100 to 1

05 FC:102

11/08/5000 EDBILERS 00000001 071392 09529050

## **Amendment**

In the Title:

Please amend the title to read: --MEDICAMENTS FOR THE TREATMENT OF NON-CONSTIPATED FEMALE IRRITABLE BOWEL SYNDROME--.

## In the Claims:

Please amend the claims as follows:

14. (Amended) A method of treatment according to claim 11, wherein the 5-HT3 receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, [cliansetron] <u>cilansetron</u>, itasetron, indisetron or dolasetron.

32

18. (Amended) A method of treatment according to claim 15, wherein the 5-HT3 receptor antagonist is selected from granisetron, alasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, [cliansetron] cilansetron, itasetron, indisetron or dolasetron.